ES2705027T3 - Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados - Google Patents
Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados Download PDFInfo
- Publication number
- ES2705027T3 ES2705027T3 ES11818848T ES11818848T ES2705027T3 ES 2705027 T3 ES2705027 T3 ES 2705027T3 ES 11818848 T ES11818848 T ES 11818848T ES 11818848 T ES11818848 T ES 11818848T ES 2705027 T3 ES2705027 T3 ES 2705027T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- disease
- mammal
- administration
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40190710P | 2010-08-19 | 2010-08-19 | |
| PCT/US2011/048472 WO2012024616A1 (en) | 2010-08-19 | 2011-08-19 | Methods of treating miild cognitive impairment (mci) and related discorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2705027T3 true ES2705027T3 (es) | 2019-03-21 |
Family
ID=45605447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11818848T Active ES2705027T3 (es) | 2010-08-19 | 2011-08-19 | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10449177B2 (enExample) |
| EP (1) | EP2605655B1 (enExample) |
| JP (2) | JP6250394B2 (enExample) |
| AU (1) | AU2011291506B2 (enExample) |
| BR (1) | BR112013003847A8 (enExample) |
| CA (1) | CA2808630A1 (enExample) |
| DK (1) | DK2605655T3 (enExample) |
| ES (1) | ES2705027T3 (enExample) |
| MX (1) | MX353096B (enExample) |
| WO (1) | WO2012024616A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011291506B2 (en) | 2010-08-19 | 2016-07-28 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| CA2881189A1 (en) | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| ES2769578T3 (es) | 2013-02-12 | 2020-06-26 | Buck Inst Res Aging | Hidantoínas que modulan el procesamiento de APP mediado por BACE |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| MX2016009753A (es) | 2014-01-28 | 2017-07-07 | Buck Inst For Res On Aging | Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud. |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10471029B2 (en) | 2014-03-21 | 2019-11-12 | Alzheon, Inc. | Methods for treating neurological disorders |
| CA2976258C (en) | 2015-02-18 | 2024-02-20 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| US20180200259A1 (en) * | 2015-05-18 | 2018-07-19 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOID ß |
| HUE062511T2 (hu) | 2015-09-10 | 2023-11-28 | Alzheon Inc | Alzheimer-kór kezelése egy adott betegpopulációban |
| CA3007641C (en) | 2015-12-09 | 2023-10-17 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| US20180250249A1 (en) * | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| AU2017264931B2 (en) | 2016-05-12 | 2021-02-04 | Buck Institute For Research On Aging | Compounds to promote normal processing of APP |
| CN110382543B (zh) | 2017-01-03 | 2023-12-26 | 生物蛋白有限公司 | 用于治疗衰老细胞的蛋白治疗剂 |
| US11026963B2 (en) | 2018-07-11 | 2021-06-08 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| CN110232679A (zh) * | 2019-05-24 | 2019-09-13 | 潘丹 | 一种阿尔茨海默症遗传生物标志物确定方法及系统 |
| CN114555071A (zh) | 2019-07-25 | 2022-05-27 | 学校法人东京理科大学 | 治疗、预防或改善精神/神经系统的疾病或症状的药剂 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| DK0971033T3 (da) | 1991-01-21 | 2009-12-14 | Elan Pharm Inc | Test og model til Alzheimers sygdom |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| EP0620849B1 (en) | 1992-01-07 | 2003-06-25 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| ATE198622T1 (de) | 1993-10-27 | 2001-01-15 | Elan Pharm Inc | Transgene tiere, die app allele mit der schwedischen mutation beherbergen |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| AU6383396A (en) | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO2000003819A1 (en) | 1998-07-17 | 2000-01-27 | The Penn State Research Foundation | Full form roll finishing technique |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| CN1502696A (zh) | 1998-09-24 | 2004-06-09 | �������Ŷ���Լ��������˾ | 阿尔茨海默氏疾病分泌酶 |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| JP4588221B2 (ja) | 1999-04-05 | 2010-11-24 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物 |
| US20040092511A1 (en) | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020115727A1 (en) | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| MXPA05004381A (es) | 2002-10-25 | 2006-02-10 | Collegium Pharmaceutical Inc | Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos. |
| FR2846559B1 (fr) | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| EP1724267B1 (en) | 2004-02-26 | 2013-11-06 | ASKA Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| EP1755444B1 (en) | 2004-04-21 | 2020-08-05 | Mear Holding B.V. | System for measuring pulsatile vascular resistance |
| EP1741430B1 (en) | 2004-04-30 | 2009-07-15 | National University Corporation Chiba University | Remedy for psychoneurotic diseases |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| JP2008525501A (ja) | 2004-12-23 | 2008-07-17 | ゼノポート，インコーポレイティド | セリンアミノ酸誘導のプロポフォールのプロドラッグ、その使用及び結晶体 |
| EP1874356A2 (en) | 2005-04-15 | 2008-01-09 | Board of Trustees of Michigan State University | Aminergic pharmaceutical compositions and methods |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| AU2006308889A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| CA2644458A1 (en) | 2006-03-01 | 2007-09-07 | Galderma Research & Development | Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof |
| ES2587014T3 (es) * | 2006-11-24 | 2016-10-20 | Ac Immune S.A. | Derivados de N-(metil)-piridin-2-amina para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide |
| WO2008074896A1 (en) * | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| JP2010526080A (ja) | 2007-05-03 | 2010-07-29 | アルビサー，ジャック，エル． | ホノキオール類縁体および癌治療へのそれらの使用 |
| EP2219449A4 (en) | 2007-11-16 | 2010-10-27 | Univ Arizona State | METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING |
| CL2007003877A1 (es) | 2007-12-28 | 2008-06-27 | Univ De Concepcion Lab Androma | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
| EP2273880B1 (en) | 2008-04-28 | 2014-12-31 | Zogenix, Inc. | Novel formulations for treatment of migraine |
| WO2009155054A2 (en) | 2008-05-29 | 2009-12-23 | Albany Molecular Research, Inc. | 5-ht3 receptor modulators, methods of making, and use thereof |
| US8604087B2 (en) | 2008-09-25 | 2013-12-10 | Bioland Ltd. | Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol |
| US9622977B2 (en) | 2008-10-08 | 2017-04-18 | Bioplus Life Sciences Pvt, Ltd. | Sustained release drug delivery system |
| US20100099701A1 (en) | 2008-10-20 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Isoquinolinone modulators of 5-ht3 receptors |
| CN101444508B (zh) | 2008-12-29 | 2010-10-27 | 海南瑞基药物研究有限公司 | 一种注射用托烷司琼制剂及其制备方法 |
| EP2432437A4 (en) | 2009-05-21 | 2012-12-19 | Bionex Pharmaceuticals Llc | TWO- AND ONE-LAYER DOSAGE FORMS |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US9790109B2 (en) * | 2010-04-30 | 2017-10-17 | General Electric Company | Method for sanitizing an electrodeionization device |
| AU2011291506B2 (en) | 2010-08-19 | 2016-07-28 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| WO2013123426A1 (en) | 2012-02-18 | 2013-08-22 | Buck Institute For Research On Aging | Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions |
-
2011
- 2011-08-19 AU AU2011291506A patent/AU2011291506B2/en not_active Ceased
- 2011-08-19 EP EP11818848.1A patent/EP2605655B1/en active Active
- 2011-08-19 MX MX2013001917A patent/MX353096B/es active IP Right Grant
- 2011-08-19 DK DK11818848.1T patent/DK2605655T3/en active
- 2011-08-19 WO PCT/US2011/048472 patent/WO2012024616A1/en not_active Ceased
- 2011-08-19 US US13/213,960 patent/US10449177B2/en active Active
- 2011-08-19 JP JP2013525003A patent/JP6250394B2/ja active Active
- 2011-08-19 BR BR112013003847A patent/BR112013003847A8/pt not_active IP Right Cessation
- 2011-08-19 CA CA2808630A patent/CA2808630A1/en not_active Abandoned
- 2011-08-19 ES ES11818848T patent/ES2705027T3/es active Active
-
2016
- 2016-08-18 JP JP2016160482A patent/JP2016193944A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX353096B (es) | 2017-12-19 |
| MX2013001917A (es) | 2013-10-25 |
| AU2011291506B2 (en) | 2016-07-28 |
| EP2605655B1 (en) | 2018-10-24 |
| US20120071468A1 (en) | 2012-03-22 |
| JP6250394B2 (ja) | 2017-12-20 |
| AU2011291506A1 (en) | 2013-03-14 |
| EP2605655A1 (en) | 2013-06-26 |
| US10449177B2 (en) | 2019-10-22 |
| JP2016193944A (ja) | 2016-11-17 |
| DK2605655T3 (en) | 2019-02-04 |
| BR112013003847A2 (pt) | 2016-05-31 |
| CA2808630A1 (en) | 2012-02-23 |
| BR112013003847A8 (pt) | 2017-12-26 |
| EP2605655A4 (en) | 2014-01-08 |
| JP2013534256A (ja) | 2013-09-02 |
| WO2012024616A1 (en) | 2012-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2705027T3 (es) | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados | |
| US10835546B2 (en) | App specific BACE inhibitors (ASBIs) and uses thereof | |
| Paris et al. | Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier | |
| JP5303458B2 (ja) | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 | |
| ES2769578T3 (es) | Hidantoínas que modulan el procesamiento de APP mediado por BACE | |
| AU2008232614A1 (en) | Method for the treatment of Fabry disease using pharmacological chaperones | |
| US20220054454A1 (en) | Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions | |
| US20190192503A1 (en) | Novel methods of treating a neurodegenerative disease in a mammal in need thereof | |
| US20090192199A1 (en) | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression | |
| US9675627B2 (en) | Dosing regimens for treating and/or preventing cerebral amyloidoses | |
| US20130102538A1 (en) | Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity | |
| WO2025095099A1 (ja) | 前頭側頭葉変性症治療剤及び治療用組成物 |